CTOs on the Move


 
RxHub LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.rxhub.net
  • 380 Saint Peter St Ste 530
    Saint Paul, MN USA 55102
  • Phone: 651.855.3000

Executives

Name Title Contact Details

Similar Companies

4D Pharmacy Management Systems Inc

4D Pharmacy Management Systems Inc is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kalypsys

Kalypsys, Inc. is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santen

At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.

Assertio Therapeutics

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company.